CA2617600A1 - Reovirus attenue - Google Patents

Reovirus attenue Download PDF

Info

Publication number
CA2617600A1
CA2617600A1 CA002617600A CA2617600A CA2617600A1 CA 2617600 A1 CA2617600 A1 CA 2617600A1 CA 002617600 A CA002617600 A CA 002617600A CA 2617600 A CA2617600 A CA 2617600A CA 2617600 A1 CA2617600 A1 CA 2617600A1
Authority
CA
Canada
Prior art keywords
reovirus
attenuated
seq
set forth
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002617600A
Other languages
English (en)
Inventor
Randal N. Johnston
Manbok Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Technologies International Inc
Original Assignee
University Technologies International, Inc.
Randal N. Johnston
Manbok Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Technologies International, Inc., Randal N. Johnston, Manbok Kim filed Critical University Technologies International, Inc.
Publication of CA2617600A1 publication Critical patent/CA2617600A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12261—Methods of inactivation or attenuation
    • C12N2720/12264—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002617600A 2005-08-01 2006-07-31 Reovirus attenue Abandoned CA2617600A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70460405P 2005-08-01 2005-08-01
US60/704,604 2005-08-01
PCT/IB2006/004149 WO2007099401A2 (fr) 2005-08-01 2006-07-31 Reovirus attenue

Publications (1)

Publication Number Publication Date
CA2617600A1 true CA2617600A1 (fr) 2007-09-07

Family

ID=38459397

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002617600A Abandoned CA2617600A1 (fr) 2005-08-01 2006-07-31 Reovirus attenue

Country Status (4)

Country Link
US (1) US10260049B2 (fr)
EP (1) EP1917351A4 (fr)
CA (1) CA2617600A1 (fr)
WO (1) WO2007099401A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
JP5577103B2 (ja) 2007-03-12 2014-08-20 オンコリティクス バイオテク，インコーポレーテッド 改変配列を有するレオウイルス
US10369171B2 (en) * 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
TW200909581A (en) * 2007-05-21 2009-03-01 Oncolytics Biotech Inc Mutant reoviruses and methods of making and using
KR20210098202A (ko) * 2020-01-31 2021-08-10 바이로큐어 주식회사 레오바이러스를 유효성분으로 포함하는 대장염의 예방 또는 치료용 조성물
US20240041959A1 (en) * 2020-12-22 2024-02-08 Virocure, Inc. Novel modified reovirus and use thereof
KR102654464B1 (ko) * 2021-09-24 2024-04-09 바이로큐어 주식회사 레오바이러스 기반 신규한 백신플랫폼 및 이의 용도

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5101068A (en) 1990-02-16 1992-03-31 Prototek Inc. Magnesium fluoromalonates
US5210272A (en) 1990-02-16 1993-05-11 Prototek, Inc. Process for forming a fluoromethyl ketone
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
CA2305269C (fr) 1997-10-09 2012-07-03 Pro-Virus, Inc. Traitement de neoplasmes par des virus
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
EP1390046A4 (fr) 1999-04-15 2005-04-20 Wellstat Biologics Corp Traitement de neoplasmes avec des virus
CA2386920C (fr) 1999-09-17 2012-01-24 Pro-Virus, Inc. Virus oncolytique
CA2388807C (fr) * 1999-11-12 2013-08-06 Matthew C. Coffey Virus pour le traitement des troubles de la proliferation cellulaire
US6605589B1 (en) 2000-03-31 2003-08-12 Parker Hughes Institute Cathepsin inhibitors in cancer treatment
AR028040A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
CN1250711C (zh) * 2000-06-26 2006-04-12 威尔斯达特生物制剂公司 用病毒清除细胞
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
DE60142485D1 (de) 2000-11-09 2010-08-12 Oncolytics Biotech Inc Verfahren zur Beurteilung von zellulären proliferativen Erkrankungen
EP1335737A2 (fr) 2000-11-20 2003-08-20 Oncolytics Biotech, Inc. Procede d'apport optimal d'un virus a une masse de tumeur solide
CA2430495A1 (fr) 2000-12-01 2002-06-06 University Of Ottawa Virus oncolytique
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
ES2500645T3 (es) * 2001-03-16 2014-09-30 Oncolytics Biotech Inc. Método para extracción de virus de un cultivo celular
JP4916641B2 (ja) 2001-05-11 2012-04-18 ウェルスタット バイオロジクス コーポレイション 腫瘍崩壊性ウイルス治療
US20040115170A1 (en) * 2001-11-30 2004-06-17 Brown Earl Garnet Oncolytic virus
CA2374388C (fr) 2002-02-28 2005-07-12 Matthew C. Coffey L'utilisation de ribozymes pour la detection d'agents adventifs
CA2478616C (fr) 2002-03-26 2012-05-29 Oncolytics Biotech Inc. Utilisation d'adenovirus mutes dans les genes va en vue du traitement du cancer
EP1501921B2 (fr) 2002-04-30 2012-07-25 Oncolytics Biotech Inc. Procede ameliore de purification de virus
DE60322885D1 (de) 2002-05-09 2008-09-25 Oncolytics Biotech Inc Methode zur schmerzbekämpfung mit onkolytischen viren
DK1505993T3 (da) 2002-05-10 2012-05-21 Oncolytics Biotech Inc Sensibilisering af neoplastiske celler for stråleterapi med onkolytiske vira
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
CA2411397C (fr) 2002-11-07 2013-01-22 Oncolytics Biotech Inc. Reovirus pour le traitement de troubles de la proliferation cellulaire induits par ral
JP2006519784A (ja) * 2003-01-28 2006-08-31 シャンハイ、サンウエイ、バイアテク、カムパニ、リミティド 原発癌および転移癌に対する治療（ａ２）温熱療法と腫瘍溶解の同時治療（ａ３）
CA2422245A1 (fr) 2003-03-14 2004-09-14 Oncolytics Biotech Inc. Methodes de traitement de troubles de la proliferation cellulaire
CA2434995A1 (fr) 2003-07-07 2005-01-07 Oncolytics Biotech Inc. Virus oncolytiques pour le traitement de tumeurs caracterisees par une activite de la pp2a ou de rac
WO2005002607A2 (fr) 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Virus oncolytiques pour le traitement de neoplasmes a pp2a et rac activees
CA2436196A1 (fr) 2003-07-25 2005-01-25 Oncolytics Biotech Inc. Virus oncolytique pour eliminer les cellules de tumeurs malignes lymphoides presentes dans des melanges de cellules
CA2435967A1 (fr) * 2003-07-25 2005-01-25 Oncolytics Biotech, Inc. Reovirus pour le traitement de tumeurs malignes lymphoides
WO2005014017A1 (fr) 2003-08-08 2005-02-17 Yuji Shino Composition medicinale pour traiter le cancer
US20050214266A1 (en) * 2004-03-12 2005-09-29 Oncolytics Biotech Inc. Combination of transplantation and oncolytic virus treatment
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
US10653725B2 (en) 2015-08-17 2020-05-19 Aker Biomarine Antarctic As Methods for improving health of farmed fish

Also Published As

Publication number Publication date
WO2007099401A3 (fr) 2008-03-13
WO2007099401A2 (fr) 2007-09-07
EP1917351A4 (fr) 2009-12-16
US10260049B2 (en) 2019-04-16
EP1917351A2 (fr) 2008-05-07
US20090214479A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
US10668119B2 (en) Attenuated reovirus
US10434169B2 (en) Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
US10260049B2 (en) Attenuated reovirus
Yang et al. Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates
JP4225577B2 (ja) 新形成の治療及び予防のための細胞変性ウイルス
US10369171B2 (en) Attenuated reoviruses for selection of cell populations
CN101027394A (zh) 修饰的溶瘤病毒
Berry et al. Potent oncolytic activity of human enteroviruses against human prostate cancer
Alkassar et al. The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo
Kim et al. Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells
JP5615865B2 (ja) 外来性の物質の検出におけるリボザイムの使用
Sahin et al. Development of oncolytic reovirus for cancer therapy
US20220088096A1 (en) Oncolytic myxoma virus expressing fast p14 to treat hematological cancer
US20080206199A1 (en) Chimeric Herpes Viruses and Uses Thereof
Zerboni et al. Varicella-zoster virus infection of a human CD4-positive T-cell line
CA2436196A1 (fr) Virus oncolytique pour eliminer les cellules de tumeurs malignes lymphoides presentes dans des melanges de cellules
CA2435967A1 (fr) Reovirus pour le traitement de tumeurs malignes lymphoides
CN111041001A (zh) 治疗kras突变型肿瘤的安全型柯萨奇病毒及其药物组合物
Ahsan et al. Polyomaviruses: an overview
US7264923B2 (en) Norovirus infected cell cultures and uses therefor
US20210008136A1 (en) Improved Oncolytic Reovirus
Zita Mechanisms of Reovirus-Induced Cardiac Pathology
Gao Genomic and biologic comparisons of Cyprinid herpesvirus 3 strains: a journey into virus evolution in vitro and in vivo
Jandick et al. CREATION AND CHARACTERIZATION OF A RECOMBINANT MAMMALIAN ORTHOREOVIRUS EXPRESSING HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 PEPTIDES
Wollenberg Tweaking reovirus T3D to boost the oncolytic potency

Legal Events

Date Code Title Description
FZDE Dead